Navigation Links
Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
Date:5/25/2011

LONDON, May 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK.

Results from Primary Dosing Period and Ongoing Extension of Phase 2b Combination Study with Allopurinol

Results presented from the ongoing blinded extension portion of Ardea's Phase 2b study (study 203) of lesinurad in patients who did not achieve target on allopurinol therapy alone demonstrated that for those patients who have reached week 28 of the extension period, 91 percent of those patients receiving lesinurad in combination with allopurinol achieved serum urate (sUA) levels below the clinically important target of 6 mg/dL.  Importantly, continued reductions in sUA were observed beyond the initial 28 days of dosing with a majority of the responding patients remaining on a 200 mg dose of lesinurad thus far in the extension period.  These preliminary results are from the extension portion of a 28-day, randomized, double-blind, placebo-controlled Phase 2b study evaluating lesinurad in combination with allopurinol in 208 gout patients with elevated sUA greater than or equal to 6 mg/dL who were not adequately responding despite being on a stable dose of allopurinol.  Following the 28-day primary dosing period and at least a two-week washout, 126 patients entered the optional extension period and restarted dosing with 200 mg of lesinurad or placebo.  Non-responding patients can be escalated up to 400 mg or 600 mg of lesinurad, at the investigators' discretion.  Currently, 30 patients have been dosed for at least 6 m
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... 2015 La solución de ... cuidado al paciente a lo ... Royal Philips  (NYSE: PHG, AEX: PHIA) ... Cardiovascular , un sistema web de gestión de imágenes ... y compartir imágenes cardiovasculares e información en cualquier momento, ...
(Date:8/28/2015)... 2015  CytomX Therapeutics, Inc., a biopharmaceutical company developing ... the filing of a registration statement on Form S-1 ... to a proposed initial public offering of its common ... the price range for the offering have not yet ... under the symbol "CTMX" on the NASDAQ Global Market. ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... KINNELON, N.J., Sept. 8, 2011 Life Recovery Systems ... three-year agreement by Premier Purchasing Partners, LP, the group ... the ThermoSuit System available by contract to its more ... award, LRS,s first GPO contract, Robert Neary, LRS Director ...
... Elusys Therapeutics, Inc. (Elusys), a  biopharmaceutical company developing ... awarded the first U.S. Government contract to develop ... use via intramuscular injection (IM). The five year ... multiple animal efficacy studies as well as human ...
Cached Medicine Technology:Life Recovery Systems Awarded Contract With Premier for Patient Temperature Management 2Life Recovery Systems Awarded Contract With Premier for Patient Temperature Management 3Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection 2Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection 3
(Date:8/30/2015)... ... 2015 , ... Negotiating an FDA Import Hold Crisis:, Strategies for Challenging FDA ... http://www.fdanews.com/importholdcrisis , US authorities are holding imports more than ever before, particularly at ... alerts on an uptick and a new final rule, having a top-notch import compliance ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... announce that Partner Daniel M. Kotin was recently elected to membership in the ... the highest degree of peer recognition and outstanding professionalism. , ABOTA is ...
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ( http://www.inhealthmedia.com ... Global Communications Director for InHealth Media. Mr. Spector comes with a wide ... years doing on-air television, producing shows, on air-radio and media relations. , ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products ... Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products International. ... on your goals. Kathleen graduated from Florida State University with a Bachelor ...
(Date:8/29/2015)... (PRWEB) , ... August 30, 2015 , ... ... Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent ... than a simple digital handwritten signature. , Clinical trial sites can ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 3Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4
... , MINNEAPOLIS, Sept. 21 Target(R) announces that ... Pharmacy locations nationwide. The Centers for Disease Control and Prevention ... With more than 1,500 pharmacy locations, guests can easily ... , , No appointment is necessary for ...
... Visit ... ... Foundation (APF) says economic pain from the recession is contributing to acute (short-term) physical ... consumer education initiative with RealAge.com to provide tips and information on preventing and treating ...
... cleared to go, experts say , MONDAY, Sept. 21 (HealthDay ... long as they don,t have any complications. , That,s ... by the American College of Obstetricians and Gynecologists (ACOG). It ... Gynecology . , Since 2001, "a number of observational studies ...
... ST. LOUIS, Sept. 21 In simultaneous releases published ... for stronger action against indoor radon, the leading cause of lung ... The central WHO recommendation is to lower radon gas levels ... level doubles the number of U.S. homes needing radon control systems ...
... , , CHARLESTON, S.C., ... be stopping in South Carolina throughout the week of September ... uninsured and financially struggling South Carolinians access information on programs ... the state,s unemployment rate now hitting 11.8 percent, the Partnership ...
... DIEGO, Sept. 21 US Farms, Inc. (Pink Sheets: USFM), ... to the International Aloe Science Council, Inc. , , ... excited to become an acting member of the International Aloe Science ... for our company moving forward. The Aloe Industry worldwide as a ...
Cached Medicine News:Health News:Seasonal Flu Vaccinations Will Be Available at Target Pharmacy Locations Nationwide Beginning September 20th 2Health News:Seasonal Flu Vaccinations Will Be Available at Target Pharmacy Locations Nationwide Beginning September 20th 3Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals, Inc. and RealAge.com Launch Effort to Educate Americans 2Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals, Inc. and RealAge.com Launch Effort to Educate Americans 3Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals, Inc. and RealAge.com Launch Effort to Educate Americans 4Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals, Inc. and RealAge.com Launch Effort to Educate Americans 5Health News:With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals, Inc. and RealAge.com Launch Effort to Educate Americans 6Health News:Flying OK for Most Pregnant Women 2Health News:World Health Organization Launches New Attack on Lung Cancer 2Health News:Partnership for Prescription Assistance Prepared to Help South Carolina Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help South Carolina Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help South Carolina Workers Hurt by Recession 4Health News:US Farms, Inc. Announces Membership to International Aloe Science Council, Inc. 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: